These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1603214)

  • 21. Steroids in the management of PBC: why do we need them?
    Blendis L
    Gastroenterology; 2005 Oct; 129(4):1350-2. PubMed ID: 16230089
    [No Abstract]   [Full Text] [Related]  

  • 22. Ursodeoxycholic acid therapy in primary biliary cirrhosis.
    Podda M; Crosignani A; Battezzati PM; Quagliuolo M; Valsania C; Invernizzi P; Zuin M
    Ital J Gastroenterol; 1996; 28(2):114-7. PubMed ID: 8782007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
    Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for therapy of autoimmune liver disease.
    Ishibashi H; Komori A; Shimoda S; Gershwin ME
    Semin Liver Dis; 2007 May; 27(2):214-26. PubMed ID: 17520519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Myth and realities of antifibrotic medication].
    Kershenobich D
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():60-1. PubMed ID: 17471861
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hashimoto's encephalopaty associated with primary biliary cirrhosis and vitiligo].
    Peña-Irún Á
    Med Clin (Barc); 2016 Mar; 146(6):e31-2. PubMed ID: 26589737
    [No Abstract]   [Full Text] [Related]  

  • 27. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary biliary cirrhosis (PBC) (symptomatic, asymptomatic)].
    Okuaki Y; Toda G
    Ryoikibetsu Shokogun Shirizu; 1995; (7):560-4. PubMed ID: 8749554
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of primary biliary cirrhosis with ursodeoxycholic acid].
    Lotterer E; Fleig WE
    Z Gastroenterol; 1993 Oct; 31(10):633-5. PubMed ID: 8256481
    [No Abstract]   [Full Text] [Related]  

  • 30. [Primary biliary cirrhosis. Primary sclerosing cholangitis].
    Corpechot C; Chazouilleres O
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):325-32. PubMed ID: 12769103
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid without liver biopsy?].
    Siboni AH
    Ugeskr Laeger; 2004 Aug; 166(32):2688; author reply 2688. PubMed ID: 15347178
    [No Abstract]   [Full Text] [Related]  

  • 32. [Ursodeoxycholic acid in primary biliary cirrhosis. 1: Therapeutic approaches up to now and the rationale for treatment with ursodeoxycholic acid].
    Eisenburg J; Eder M; Spengler U; Berg PA; Caselmann W; Mannes AG; Muntau A
    Fortschr Med; 1988 Nov; 106(34):691-4. PubMed ID: 3061911
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy.
    Zukowski TH; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1998 Jun; 93(6):958-61. PubMed ID: 9647028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
    Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
    Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ursodeoxycholic acid in the treatment of primary biliary liver cirrhosis].
    Poupon R
    Gastroenterol Clin Biol; 1994; 18(2 Pt 3):T5-8. PubMed ID: 8045357
    [No Abstract]   [Full Text] [Related]  

  • 36. [The treatment of primary biliary cirrhosis. Its current status].
    Berenguer Lapuerta J; Nos Mateu P; Siles Moreno MS
    Rev Esp Enferm Dig; 1991 Nov; 80(5):324-30. PubMed ID: 1768472
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy.
    Terasaki S; Nakanuma Y; Ogino H; Unoura M; Kobayashi K
    Am J Gastroenterol; 1991 Sep; 86(9):1194-9. PubMed ID: 1882800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [What is guaranteed in the therapy of primary biliary cirrhosis with bile acids?].
    Leuschner U
    Internist (Berl); 1990 Nov; 31(11):707-11. PubMed ID: 2289857
    [No Abstract]   [Full Text] [Related]  

  • 39. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis.
    Dimoulios P; Kolios G; Notas G; Matrella E; Xidakis C; Koulentaki M; Tsagarakis N; Kouroumalis A; Kouroumalis E
    Aliment Pharmacol Ther; 2005 Feb; 21(3):227-34. PubMed ID: 15691296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
    Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
    Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.